Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scen...

por Allman, Kimberly D., Ryan, Joanne C., Clair, Andrew, Yenser-Wood, Sarah
Publicado 2019

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

por Barata, Pedro C, Chehrazi-Raffle, Alexander, Allman, Kimberly D, Asnis-Alibozek, Aviva, Kasturi, Vijay, Pal, Sumanta K
Publicado 2023

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

por Ornstein, Moshe C., Wood, Laura S., Hobbs, Brian P., Allman, Kimberly D., Martin, Allison, Bevan, Michael, Gilligan, Timothy D., Garcia, Jorge A., Rini, Brian I.
Publicado 2019

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

por Zahoor, Haris, Barata, Pedro C., Jia, Xuefei, Martin, Allison, Allman, Kimberly D., Wood, Laura S., Gilligan, Timothy D., Grivas, Petros, Ornstein, Moshe C., Garcia, Jorge A., Rini, Brian I.
Publicado 2018

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

por Barata, Pedro Coelho, De Liano, Alfonso Gomez, Mendiratta, Prateek, Crolley, Valerie, Szabados, Bernadett, Morrison, Laura, Wood, Laura, Allman, Kimberly, Tyler, Allison, Martin, Allison, Gilligan, Timothy, Grivas, Petros, Ornstein, Moshe, Garcia, Jorge A., Powles, Thomas, Rini, Brian I.
Publicado 2018